PASG Passage Bio Inc.

Biotech Analyst Ratings

Latest News

1. 20 May 2022 Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

   PHILADELPHIA, May 20, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees.
   

   Passage Bio granted options to purchase 79,600 shares of common stock to these employees as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.69 per share, which is equal to the closing price of Passage Bio's common stock on May 16, 2022, the grant date of the options.

   The shares subject to the Inducement Options will vest over four years, with 25 percent of the shares vesting on…

   View Full Article
2. 18 May 2022 Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting

   • Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregivers
     
   • Interim safety data at 13 and seven months from patients in Cohort 1 of the Imagine-1 clinical trial showed low dose of PBGM01 was well tolerated and had a favorable safety profile
   • Global Phase 1/2 study continues to enroll patients, with interim safety and biomarker data from Cohorts 2 and 3 expected in 2H22
     

   PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the presentation of longer-term clinical and biomarker data from Cohort 1…

   View Full Article
3. 16 May 2022 Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights

   • Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22
     
   • Dosed first patient in Cohort 1 in GALax-C clinical trial in infantile Krabbe disease; interim safety and biomarker data expected by year-end 2022
   • Submitted IND for Phase 1/2 clinical program of PBML04 for metachromatic leukodystrophy
   • Completed strategic prioritization to extend cash runway into 2Q24
   • Management to host conference call today at 8:30 a.m. ET
     

   PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders…

   View Full Article
4. 09 May 2022 Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022

   PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 16, 2022, to report its first quarter 2022 financial results and discuss recent business highlights.
   

   To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 6960234. A live audio webcast of the event will be available on the Investors & News section of Passage Bio's website at investors.passagebio.com. The archived webcast will be available on Passage Bio's…

   View Full Article
5. 02 May 2022 Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

   PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is being held in Washington D.C. and virtually from May 16 to 19, 2022.
   

   Late-breaker oral presentation details:

   Title: Interim Safety, Biomarker, and Efficacy Data From Imagine-1: A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Single Dose, ICM Administration…

   View Full Article